New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg and clinical trial completers lost an average of 9.2% (Novo Nordisk)
Diabetes News Service
New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg and clinical trial completers lost an average of 9.2% (Novo Nordisk)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales